TransCode Therapeutics, Inc. (RNAZ) financial statements and ratios from SEC XBRL: revenue $79198.00 (TTM), net margin -43765.1%, revenue growth 11478.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $79198.00 |
| Net Margin | -43765.1% |
| Revenue Growth (YoY) | 11478.7% |
| EPS Growth (YoY) | 11.6% |
| FCF Growth (YoY) | 46.2% |
| Price / Sales | 212.63 |
| Altman Z-Score | -1.26 (distress) |
| Sector P/E (Healthcare) | 21.7 |
RNAZ overview · RNAZ earnings · RNAZ KPIs · RNAZ investor relations · RNAZ ownership · RNAZ peers · RNAZ filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.